Table 1.
Characteristics of NeuroEDIC participants at DCCT baseline, DCCT closeout, and EDIC years 13–14
| Characteristic | DCCT baseline | DCCT closeout | EDIC years 13–14 |
|---|---|---|---|
| Age (years) | |||
| INT (n = 603) | 27 ± 7* | 34 ± 7* | 48 ± 7* |
| CONV (n = 583) | 27 ± 7 | 33 ± 7 | 47 ± 7 |
| Female | |||
| INT | 294 (49) | 294 (49) | 294 (49) |
| CONV | 268 (46) | 268 (46) | 268 (46) |
| Height (cm) | |||
| INT | 171 ± 10 | 172 ± 10 | 171 ± 9 |
| CONV | 172 ± 10 | 172 ± 10 | 173 ± 10 |
| Weight (kg) | |||
| INT | 68 ± 11 | 78 ± 14† | 84 ± 17 |
| CONV | 70 ± 13 | 75 ± 13 | 84 ± 17 |
| BMI (kg/m2) | |||
| INT | 23 ± 3 | 27 ± 4† | 29 ± 5 |
| CONV | 24 ± 3 | 25 ± 3 | 28 ± 5 |
| BMI >30 (kg/m2) | |||
| INT | 7 ± 1 | 115 ± 20† | 202 ± 34 |
| CONV | 10 ± 2 | 27 ± 5 | 173 ± 30 |
| Diabetes duration (years) | |||
| INT | 6 ± 4 | 12 ± 5 | 26 ± 5 |
| CONV | 6 ± 4 | 12 ± 5 | 26 ± 5 |
| A1C (%) | |||
| INT | 9.1 ± 1.6 | 7.3 ± 1.0† | 7.8 ± 1.2 |
| CONV | 8.9 ± 1.6 | 9.1 ± 1.5 | 7.8 ± 1.2 |
| Systolic blood pressure (mmHg) | |||
| INT | 113 ± 12† | 116 ± 11 | 121 ± 14 |
| CONV | 115 ± 12 | 116 ± 12 | 120 ± 14 |
| Diastolic blood pressure (mmHg) | |||
| INT | 72 ± 9 | 75 ± 9 | 74 ± 9 |
| CONV | 73 ± 9 | 74 ± 9 | 73 ± 9 |
| Total cholesterol (mg/dl) | |||
| INT | 177 ± 33 | 180 ± 31 | 176 ± 36 |
| CONV | 174 ± 33 | 183 ± 36 | 173 ± 35 |
| LDL cholesterol (mg/dl) | |||
| INT | 111 ± 29 | 112 ± 27 | 103 ± 30 |
| CONV | 108 ± 29 | 114 ± 31 | 100 ± 31 |
| Current smoker | |||
| INT | 125 (21) | 134 (22) | 87 (14) |
| CONV | 111 (19) | 119 (20) | 79 (14) |
| Any ACE inhibitors or angiotensin receptor II blockers‡ | |||
| INT | 290 (48) | ||
| CONV | 301 (52) | ||
| Medication for neuropathic pain in hands/feet | |||
| INT | 41 (7) | ||
| CONV | 35 (6) |
Data are means ± SD or n (%).
*P < 0.05 former intensive treatment group (INT) vs. former conventional treatment group (CONV).
†P < 0.01 INT vs. CONV.
‡Data on medication use was not collected during the DCCT.